AU2002367172A1 - 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents - Google Patents
2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agentsInfo
- Publication number
- AU2002367172A1 AU2002367172A1 AU2002367172A AU2002367172A AU2002367172A1 AU 2002367172 A1 AU2002367172 A1 AU 2002367172A1 AU 2002367172 A AU2002367172 A AU 2002367172A AU 2002367172 A AU2002367172 A AU 2002367172A AU 2002367172 A1 AU2002367172 A1 AU 2002367172A1
- Authority
- AU
- Australia
- Prior art keywords
- prolylpeptidase
- inducers
- diamino
- apoptosis
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 2,4-diamino-pyrimidine derivative compounds Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000411 inducer Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34304701P | 2001-12-21 | 2001-12-21 | |
| US60/343,047 | 2001-12-21 | ||
| PCT/US2002/041146 WO2003055489A1 (en) | 2001-12-21 | 2002-12-20 | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002367172A1 true AU2002367172A1 (en) | 2003-07-15 |
Family
ID=23344452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002367172A Abandoned AU2002367172A1 (en) | 2001-12-21 | 2002-12-20 | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002367172A1 (en) |
| WO (1) | WO2003055489A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001096A (en) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. |
| AU2004265288A1 (en) | 2003-07-30 | 2005-02-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| RU2356901C2 (en) * | 2003-07-30 | 2009-05-27 | Райджел Фармасьютикалз, Инк. | 2,4-pyrimidindiamine compounds having effect in case of autoimmune disorders |
| US20050113398A1 (en) * | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| WO2005063722A1 (en) * | 2003-12-19 | 2005-07-14 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
| CN101115761B (en) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| CN100387602C (en) * | 2005-07-08 | 2008-05-14 | 张晴龙 | A kind of chelerythrine compound and preparation method thereof |
| AR063527A1 (en) | 2006-10-23 | 2009-01-28 | Cephalon Inc | FUSIONED BICYCLE DERIVATIVES OF 2,4-DIAMINOPIRIMIDINE AS ALK AND C-MET INHIBITORS |
| JP5713367B2 (en) | 2010-06-04 | 2015-05-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Aminopyrimidine derivatives as LRRK2 modulators |
| BR112013011600B1 (en) | 2010-11-10 | 2022-01-11 | Genentech, Inc | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES, THEIR USE AND COMPOSITION INCLUDING THEM |
| PL2701708T3 (en) | 2011-04-29 | 2020-11-02 | The Penn State Research Foundation | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
| RU2014137448A (en) * | 2012-02-17 | 2016-04-10 | Эббви Инк. | DIAMINOPYRIMIDINES SUITABLE AS INHIBITORS OF RESPIRATORY-SYNCITIAL HUMAN VIRUS (RSV) |
| CN103408501B (en) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | Benzylpyrimidine derivative, its preparation method and medicinal use thereof |
| CN106362696A (en) * | 2016-10-17 | 2017-02-01 | 江苏理工学院 | Preparation method and application of surface modified nano aluminum oxide |
| CN111122523B (en) * | 2019-12-06 | 2021-09-28 | 山西大学 | Quick recognition Ag+Cys-combined molecular logic gate with three-phase output function and construction method thereof |
| CN111620852B (en) * | 2020-01-19 | 2023-05-09 | 镇江植生源农业科技有限公司 | 5-chloro-pyrimidine-2, 4-diamine compound, and preparation method and application thereof |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2861560D1 (en) * | 1977-11-28 | 1982-03-04 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6485955B1 (en) * | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
| ATE232521T1 (en) * | 1998-03-27 | 2003-02-15 | Janssen Pharmaceutica Nv | HIV-INHIBITING PYRIMIDINE DERIVATIVES |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| RS94703A (en) * | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
-
2002
- 2002-12-20 AU AU2002367172A patent/AU2002367172A1/en not_active Abandoned
- 2002-12-20 WO PCT/US2002/041146 patent/WO2003055489A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003055489A1 (en) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002364211A1 (en) | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002367172A1 (en) | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002361846A1 (en) | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| AU2002339157A1 (en) | Inhibitors of the notch signalling pathway for use in the treatment of cancer | |
| IL157425A0 (en) | Treatment of solid tumours with paramycin derivatives | |
| WO2003073999A3 (en) | Pini-modulating compounds and methods of use thereof | |
| AU2002258399A1 (en) | Use of trail and antiprogestins for treating cancer | |
| WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
| AU2002364364A1 (en) | Method of treating apoptosis and compositions thereof | |
| AU6048201A (en) | Quinazoline derivatives for the treatment of tumours | |
| AU2002252456A1 (en) | Combination treatment of pancreatic cancer | |
| AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
| AU2002328952A1 (en) | Irinotecan for treatment of cancer | |
| AU2002252227A1 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
| IL161059A0 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| MXPA03008582A (en) | Agents and methods for treatment of cancer. | |
| AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
| AU2003249713A1 (en) | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis | |
| IL145397A0 (en) | Compositions and methods for treatment of cancer | |
| PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
| AU2001232060A1 (en) | Use of cyp1b1 inhibitors for treating cancer | |
| AUPR644301A0 (en) | Method and composition for treatment of cancer | |
| AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
| AU2002366195A1 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| AU2003284787A1 (en) | Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |